| Company Name: |
Credit Asia Chemical Co., Ltd.
|
| Tel: |
+86 (21) 61124340 |
| Email: |
|
| Products Intro: |
Product Name:Thiazolidine,3-[(2S,3S)-2-aMino-3-Methyl-1-oxopentyl]-, (2E)-2-butenedioate (2:1)
CAS:251572-86-8
Purity:98% HPLC Package:50g;100g;500g ;1kg;
|
| Company Name: |
MedBioPharmaceutical Technology Inc
|
| Tel: |
021-69568360 18916172912 |
| Email: |
order@med-bio.cn |
| Products Intro: |
Product Name:Thiazolidine,3-[(2S,3S)-2-aMino-3-Methyl-1-oxopentyl]-, (2E)-2-butenedioate (2:1)
CAS:251572-86-8
Purity:98% Package:5mg; 10mg Remarks:Medbio
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
| Products Intro: |
Product Name:P32/98
CAS:251572-86-8
Purity:NULL Package:10mg;1mg;25mg;5mg Remarks:NULL
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:P32/98 (hemifumarate)
CAS:251572-86-8
Purity:98% Package:100 mg；5 mg；50 mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:P32/98
CAS:251572-86-8
Purity:95% Package:1mg;5mg;10mg
|
|
| | Thiazolidine,3-[(2S,3S)-2-aMino-3-Methyl-1-oxopentyl]-, (2E)-2-butenedioate (2:1) Basic information |
| | Thiazolidine,3-[(2S,3S)-2-aMino-3-Methyl-1-oxopentyl]-, (2E)-2-butenedioate (2:1) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | ≤1mg/ml in ethanol;15mg/ml in DMSO;5mg/ml in dimethyl formamide | | form | crystalline solid |
| | Thiazolidine,3-[(2S,3S)-2-aMino-3-Methyl-1-oxopentyl]-, (2E)-2-butenedioate (2:1) Usage And Synthesis |
| Uses | P32/98 is a dipeptidyl peptidase IV inhibitor which is used in hypertensive patients treated with antihpertensive drugs. | | Biological Activity | ki: 126 nmp32/98 (hemifumarate) is an inhibitor of dpp iv.glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1) are responsible for >50% of nutrient-stimulated insulin secretion. after being released into the circulation, gip and glp-1 are quickly inactivated by the circulating enzyme dipeptidyl peptidase iv (dpp iv). | | in vitro | p32/98 was found to be able to block adipogenesis dose-dependently, starting at the concentration of 100 μm, and p32/98 could completely block adipogenesis in 3t3-l1 cell line at 500 μm concentration. in addition, the inhibitory effects of p32/98 was further confirmed by detecting the expression of adipocyte markers at the end of differentiation [1]. | | in vivo | in previou animal study, two groups of fa/fa zucker rats were orally treated twice daily for three months with p32/98 at 20 mg/kg/day and monthly oral glucose tolerance tests (ogtts) were conducted after drug washout. results showed that after 12 weeks of p32/98 treatment, the peak ogtt blood glucose values in the treated rats averaged 8.5 mmol/l less than in the controls. in addition, the concomitant insulin resulted in an increased early-phase insulin response in the treated group. moreover, in response to an 8.8 mmol/l glucose perfusion, pancreata from controls showed no increase in insulin secretion, while pancreata from p32/98-treated animals had a 3.2-fold rise in insulin secretion [2]. | | references | 1. han r, wang x, bachovchin w, zukowska z, osborn jw. inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation. sci rep. 2015 aug 5;5:12348. 2. j. a. pospisilik, s. g. stafford, h. u. demuth, et al. long-term treatment with the dipeptidyl peptidase iv inhibitor p32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in vdf (fa/fa) zucker rats. diabetes 51, 943-950 (2002). |
| | Thiazolidine,3-[(2S,3S)-2-aMino-3-Methyl-1-oxopentyl]-, (2E)-2-butenedioate (2:1) Preparation Products And Raw materials |
|